Zonisamide as Adjunct Therapy for Parkinson's Disease
Zonisamide 25-50 mg daily is an appropriate and effective adjunct therapy for Parkinson's disease patients with inadequate levodopa control, particularly for reducing "off" time and improving motor symptoms without increasing dyskinesia. 1
Evidence for Efficacy
The International Parkinson and Movement Disorder Society's 2025 evidence-based review assessed zonisamide as likely efficacious for treating motor fluctuations in PD patients already on levodopa therapy. 1 This recommendation is based on multiple high-quality Japanese randomized controlled trials demonstrating consistent benefit.
Motor Symptom Improvement
- Zonisamide significantly reduces UPDRS Part III motor scores by approximately 2.3-2.6 points compared to placebo when added to existing levodopa therapy. 2, 3
- The 50 mg daily dose provides significant reduction in daily "off" time by approximately 0.7 hours compared to placebo (p=0.005). 4
- Both 25 mg and 50 mg doses improve motor function without increasing dyskinesia, a critical advantage over simply increasing levodopa doses. 5, 6
Activities of Daily Living
- Zonisamide improves UPDRS Part II (activities of daily living during "off" periods) with a weighted mean difference of -0.81 points. 2
- The medication reduces wearing-off phenomena while maintaining quality of life measures. 4
Recommended Dosing Protocol
Initial dose: 25 mg once daily 7, 6
Titration schedule:
- Start at 25 mg daily for 2 weeks
- May increase to 50 mg daily after 2 weeks if needed
- Maximum studied dose is 100 mg daily, though doses above 50 mg show diminishing benefit-to-risk ratio 5
Administration:
- Can be taken with or without food 7
- Capsules should be swallowed whole 7
- Single daily dosing is as effective as divided doses 7
Critical Timing Consideration
Administer levodopa at least 30 minutes before meals to optimize absorption and avoid competition with dietary proteins. 8, 9 This timing applies to the patient's existing levodopa regimen when adding zonisamide.
Safety Profile and Monitoring
Common Adverse Effects
Somnolence is the most notable adverse effect, occurring in 6.3% of patients on 50 mg versus 2.3% on placebo. 4 This is significantly more common than with placebo (OR 2.17, p=0.006). 2
Other adverse effects at therapeutic doses (25-50 mg) occur at rates comparable to placebo, including:
- Dyskinesia (not increased versus placebo) 4, 5
- Hallucinations (not increased versus placebo) 4
- Overall adverse event incidence similar to placebo at 25 mg dose 6
Monitoring Requirements
Electrolytes and renal function: Monitor twice annually, as zonisamide is a carbonic anhydrase inhibitor with increased risk of kidney stones. 10
Weight monitoring: Zonisamide is associated with weight loss, which requires attention given that PD patients already experience disease-related weight loss. 10
Avoid doses above 50 mg initially: The 100 mg dose shows higher adverse event rates without proportional efficacy gains. 5
Drug Interactions
CYP3A4 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, phenobarbital) reduce zonisamide half-life from 46 hours to 27-38 hours. 7 However, this is unlikely to be clinically significant when adding zonisamide to stable therapy.
Carbonic anhydrase inhibitors: Do not combine zonisamide with other carbonic anhydrase inhibitors (topiramate, acetazolamide, dichlorphenamide) as this increases metabolic acidosis risk and kidney stone formation. 7
Valproate co-administration does not induce metabolism and results in longer zonisamide half-life (46 hours). 7
Special Populations
Renal or hepatic impairment: Use slower titration and more frequent monitoring, as zonisamide is metabolized hepatically and excreted renally. 7
Elderly patients: No dose adjustment needed based on age alone, though monitor more carefully for somnolence and falls risk. 5
Comparison to Alternative Strategies
A 2023 head-to-head trial compared adding zonisamide 25 mg versus increasing levodopa by 100 mg in DLB patients. 11 Zonisamide showed superior motor improvement (adjusted mean difference -6.4 points on MDS-UPDRS Part III at 24 weeks), though the study was conducted in dementia with Lewy bodies rather than pure PD. 11
Common Pitfalls to Avoid
Do not exceed 50 mg daily initially: Higher doses (100 mg) increase adverse effects without clear additional benefit in most patients. 5
Do not discontinue abruptly: Although not explicitly stated in guidelines, as an antiepileptic drug, gradual dose reduction over 2 weeks is recommended when discontinuing. 7
Do not use as monotherapy: Zonisamide is approved and studied only as adjunctive therapy to levodopa, not as initial PD treatment. 7, 1
Monitor for kidney stones: Ensure adequate hydration and monitor renal function, particularly in patients with history of nephrolithiasis. 10, 7
Population-Specific Evidence
Important limitation: All major efficacy trials were conducted exclusively in Japanese populations. 3, 6 The generalizability to other ethnic groups requires further study, though the medication is mechanistically sound and approved in Japan specifically for PD. 6